Intra-Cellular Therapies Announces Topline Results From Second Phase 3 Trial Evaluating Lumateperone As Adjunctive Therapy Patients With Major Depressive Disorder; Met Primary And Key Secondary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies announced positive topline results from its second Phase 3 trial evaluating Lumateperone as an adjunctive therapy for patients with Major Depressive Disorder. The trial met both its primary and key secondary endpoints.

June 18, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies announced positive results from its second Phase 3 trial for Lumateperone, meeting primary and key secondary endpoints. This is likely to boost investor confidence and positively impact the stock price in the short term.
The successful Phase 3 trial results for Lumateperone as an adjunctive therapy for Major Depressive Disorder are a significant milestone for Intra-Cellular Therapies. Meeting both primary and key secondary endpoints is likely to increase investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100